Company: RVRC
Filing Date: 2025-02-14
Form Type: S-1
Source: 0001213900-25-013823
Chunk: 72

Company: Revium Rx.
Filing Date: 2025-02-14
Form: S-1
Chunk 72
---
: hepatitis A and rabies; and protein vaccines: hepatitis B and acellular pertussis. Viral vector and nucleic acid (mRNA and DNA) vaccines are more novel platforms. The only viral vector vaccine licensed for human use is the Ebola vaccine by Merck.

The tremendous success of the vaccines from Pfizer-BioNTech (BNT162b2, also known as Comirnaty®) and Moderna (mRNA-1273, also known as Spikevax®) in combatting Coronavirus has demonstrated the value and rapid translational potential of lipid nanoparticles.

The Coronavirus pandemic introduced many millions of people to mRNA vaccines, saving many lives. These vaccines consist of two main components:

| ✓ | An                                                                                           
 mRNA molecule, a fragile single strand polymer of nucleic acid that instructs the host cells 
 to produce predetermined protein(s)                                                          |

| ✓ | A                                                                                           
 lipid nanoparticles (LNPs) coating that enables an efficient delivery of nucleic acids into 
 living cells.                                                                               |

Upon injection these vaccines into the muscle, the mRNA in the vaccine is taken up by muscle cells and muscle immune cells that start producing the desired protein and displaying it to specialized immune cells. Despite of wide vaccination with the newly introduced mRNA vaccines, since 2020, the rapid evolution and spread of new Covid variants have caused severe illnesses and national lockdowns, proving to the world how critical it is to prepare for future potential pandemics.

Mutations of other dangerous viruses that are easily transferred from animals to humans, such as bird flu, can erupt at any moment, bringing the global healthcare system to the brink of collapse, as well as triggering a social and economic crisis similar to what occurred during Covid. New mutations of known deadly viral diseases, such as Ebola, can pose a rapid and aggressive threat to the entire world.

LPLT by LipoVation

LipoVation’s team has been focusing on the development of Liposomal Protein-Loaded Technology (LPLT): a novel immunization platform for a variety of serious viral diseases, including Coronavirus, Ebola, Zika, HIV and others. The novel vaccine platform is expected to cover a wider range of antigens, not just the spike protein, making the vaccine potentially more effective and more potent in protecting from dangerous mutations.

<div align='center'>44</div>

The LPLT-based immunization platform is expected to:

| - | Significantly                                                                  
 improve vaccines’ efficiency – particularly for long-lasting booster vaccines. |

| - | Be                                                                                                 
 more durable